T. Rowe Price Associates
SIOX

T. Rowe Price Associates’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

T. Rowe Price Associates’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-304,577
Closed -$12.8M – 2598
2017
Q4 		$12.8M Buy
304,577
+58,147
+24% +$2.61M ﹤0.01% 1294
2017
Q3 		$13.6M Sell
246,430
-113,557
-32% -$19.2M ﹤0.01% 1285
2017
Q2 		$66.8M Buy
359,987
+84,903
+31% +$14.9M 0.01% 734
2017
Q1 		$32.9M Sell
275,084
-155,300
-36% -$16.3M 0.01% 960
2016
Q4 		$42.8M Buy
430,384
+33,150
+8% +$3.49M 0.01% 866
2016
Q3 		$44.5M Buy
397,234
+130,347
+49% +$15.6M 0.01% 850
2016
Q2 		$27.4M Buy
266,887
+97,141
+57% +$9.71M 0.01% 993
2016
Q1 		$15.6M Buy
169,746
+43,471
+34% +$4.64M ﹤0.01% 1160
2015
Q4 		$18.2M Buy
126,275
+2,467
+2% +$321K ﹤0.01% 1112
2015
Q3 		$12.8M Sell
123,808
-1,192
-1% -$140K ﹤0.01% 1245
2015
Q2 		$20.4M Buy
+125,000
New +$21.2M ﹤0.01% 1131

Other funds holding SIOX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

T. Rowe Price Associates's SIOX Position: Q1 2018 in Review

T. Rowe Price Associates sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q1 2018, closing a stake of 304,577 shares — an estimated $12.8M sold.

T. Rowe Price Associates first reported a position in SIOX in Q2 2015 and held it in 11 quarters. The position peaked at $66.8M in Q2 2017. 81 funds tracked by Wall St. Rank hold SIOX as of Q1 2018.

  • T. Rowe Price Associates reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • T. Rowe Price Associates sold 304,577 Sio Gene Therapies Inc. Common Stock shares in Q1 2018, an estimated $12.8M.
  • T. Rowe Price Associates first reported a position in Sio Gene Therapies Inc. Common Stock in Q2 2015 and held it in 11 quarters.
  • T. Rowe Price Associates's Sio Gene Therapies Inc. Common Stock position peaked at $66.8M in Q2 2017.
  • 81 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q1 2018.

Based on T. Rowe Price Associates's 13F filing for Q1 2018, filed 14 May 2018.